A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes

Incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA) and dipeptidyl peptidase-4 (DPP-4) inhibitors have gained prominence in recent years for the treatment of type 2 diabetes (T2D). Such therapies offer the potential to stimulate endogenous insulin activity in prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshali, Khalid Z., Karawagh, Abdullah M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018698/
https://www.ncbi.nlm.nih.gov/pubmed/27464858
http://dx.doi.org/10.15537/smj.2016.8.15800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018698/
https://www.ncbi.nlm.nih.gov/pubmed/27464858
http://dx.doi.org/10.15537/smj.2016.8.15800

Ejemplares similares